Indivior Pharmaceuticals (INDV) Depreciation & Amortization (CF) (2024 - 2026)

Indivior Pharmaceuticals' Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 33.33% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $9.0 million, a 43.75% decrease from a year earlier, with the FY2025 full-year figure at $10.0 million, down 37.5% from the prior year.
• Depreciation & Amortization (CF) steadied at $2.0 million in Q1 2026 per INDV's latest filing, from $2.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $5.0 million in Q1 2024 and bottomed at $2.0 million in Q3 2025.
• The 3-year median for Depreciation & Amortization (CF) is $3.0 million (2025), against an average of $3.3 million.
• Biggest YoY gain for Depreciation & Amortization (CF) was 25.0% in 2025; the steepest drop was 60.0% in 2025.
• Year by year, Depreciation & Amortization (CF) stood at $5.0 million in 2024, then sank by 60.0% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
• Per Business Quant, the three latest INDV Depreciation & Amortization (CF) figures stand at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025).